Genmab A/S (NASDAQ:GMAB) Given Average Rating of "Hold" by Analysts
Genmab A/S (NASDAQ:GMAB) Given Average Rating of "Hold" by Analysts
Shares of Genmab A/S (NASDAQ:GMAB – Get Rating) have been given a consensus recommendation of "Hold" by the twelve brokerages that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $547.62.
MarketBeat Ratings报告称，Genmab A/S（纳斯达克股票代码：GMAB — 获取评级）的股票已被目前报道该股的十二家经纪公司一致建议 “持有”。一位分析师对该股进行了卖出评级，七位分析师给出了持有评级，两位分析师给出了买入评级。去年发布该股报告的经纪商的1年平均目标价格为547.62美元。
Several equities analysts have recently weighed in on GMAB shares. TheStreet raised shares of Genmab A/S from a "c+" rating to a "b" rating in a research report on Wednesday, August 31st. SVB Leerink increased their price objective on shares of Genmab A/S from $30.00 to $31.00 and gave the company a "market perform" rating in a research report on Thursday, August 11th. Morgan Stanley increased their price objective on shares of Genmab A/S from $29.00 to $31.00 and gave the company an "underweight" rating in a research report on Monday, August 15th. HC Wainwright increased their price objective on shares of Genmab A/S from $49.00 to $51.00 and gave the company a "buy" rating in a research report on Monday, August 22nd. Finally, BMO Capital Markets began coverage on shares of Genmab A/S in a research note on Thursday, June 23rd. They issued a "market perform" rating and a $34.73 price target on the stock.
几位股票分析师最近对GMAB的股票进行了权衡。TheStreet在8月31日星期三的一份研究报告中将Genmab A/S的股票评级从 “c+” 上调至 “b” 评级。SVB Leerink在8月11日星期四的一份研究报告中将Genmab A/S股票的目标股价从30.00美元上调至31.00美元，并将该公司评为 “市场表现”。摩根士丹利将Genmab A/S股票的目标股价从29.00美元上调至31.00美元，并在8月15日星期一的一份研究报告中将该公司评为 “减持”。HC Wainwright在8月22日星期一的一份研究报告中将Genmab A/S股票的目标股价从49.00美元上调至51.00美元，并将该公司评为 “买入”。最后，BMO Capital Markets在6月23日星期四的一份研究报告中开始报道Genmab A/S的股票。他们发布了 “市场表现” 评级和34.73美元的目标股价。
Genmab A/S Trading Up 0.1 %
Genmab A/S 交易量上涨0.1％
Shares of GMAB opened at $36.46 on Friday. Genmab A/S has a 12 month low of $26.19 and a 12 month high of $47.28. The firm has a fifty day simple moving average of $35.65 and a 200 day simple moving average of $33.88. The stock has a market capitalization of $23.99 billion, a price-to-earnings ratio of 40.51, a PEG ratio of 1.36 and a beta of 0.85.
周五，GMAB的股价开盘价为36.46美元。Genmab A/S的12个月低点为26.19美元，为12个月高点47.28美元。该公司的五十天简单移动平均线为35.65美元，200天简单移动平均线为33.88美元。该股票的市值为239.9亿美元，市盈率为40.51，PEG比率为1.36，beta值为0.85。
Institutional Investors Weigh In On Genmab A/S
机构投资者关注Genmab A/S
A number of hedge funds have recently made changes to their positions in the stock. Private Capital Group LLC raised its holdings in Genmab A/S by 14.1% in the 2nd quarter. Private Capital Group LLC now owns 2,677 shares of the company's stock valued at $87,000 after buying an additional 331 shares during the last quarter. Wetherby Asset Management Inc. raised its holdings in Genmab A/S by 2.6% in the 4th quarter. Wetherby Asset Management Inc. now owns 14,389 shares of the company's stock valued at $569,000 after buying an additional 358 shares during the last quarter. Private Advisor Group LLC raised its holdings in Genmab A/S by 2.0% in the 2nd quarter. Private Advisor Group LLC now owns 20,522 shares of the company's stock valued at $666,000 after buying an additional 403 shares during the last quarter. Cim LLC raised its holdings in Genmab A/S by 1.7% in the 1st quarter. Cim LLC now owns 27,994 shares of the company's stock valued at $1,002,000 after buying an additional 465 shares during the last quarter. Finally, SG Americas Securities LLC raised its holdings in Genmab A/S by 9.3% in the 1st quarter. SG Americas Securities LLC now owns 6,050 shares of the company's stock valued at $219,000 after buying an additional 513 shares during the last quarter. 5.51% of the stock is currently owned by institutional investors and hedge funds.
许多对冲基金最近改变了其股票头寸。Private Capital Group LLC在第二季度将其在Genmab A/S的持股量提高了14.1％。Private Capital Group LLC在上个季度又购买了331股股票后，现在拥有该公司2677股股票，价值87,000美元。Wetherby Asset Management Inc. 在第四季度将其在Genmab A/S的持股量提高了2.6％。Wetherby Asset Management Inc. 在上个季度又购买了358股股票后，现在拥有该公司14,389股股票，价值56.9万美元。Private Advisor Group LLC在第二季度将其在Genmab A/S的持股量提高了2.0％。Private Advisor Group LLC在上个季度又购买了403股股票后，现在拥有该公司20,522股股票，价值66.6万美元。Cim LLC在第一季度将其在Genmab A/S的持股量提高了1.7％。Cim LLC在上个季度又购买了465股股票后，现在拥有该公司27,994股股票，价值1,002,000美元。最后，SG Americas Securities LLC在第一季度将其在Genmab A/S的持股量提高了9.3％。SG Americas Securities LLC在上个季度又购买了513股股票后，现在拥有该公司6,050股股票，价值21.9万美元。该股票的5.51％目前由机构投资者和对冲基金持有。
About Genmab A/S
关于 Genmab A/S
(Get Rating)
（获取评分）
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Genmab A/S 主要在丹麦开发用于治疗癌症和其他疾病的抗体疗法。该公司销售用于治疗多发性骨髓瘤（MM）患者的人类单克隆抗体DARZALEX；用于治疗甲状腺眼病的替普妥单抗；用于治疗慢性淋巴细胞白血病（CLL）和多发性硬化症的人类单克隆抗体ofatumurnab；以及用于晚期或转移性胃癌或食管癌和非小细胞肺癌的Amivantamab。
Read More
阅读更多
- Get a free copy of the StockNews.com research report on Genmab A/S (GMAB)
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
- MarketBeat: Week in Review 9/12 – 9/16
- No One Told These 3 Stocks It's a Down Week
- Is There a Cure for What is Ailing Teladoc Stock?
- 免费获取 StockNews.com 关于 Genmab A/S (GMAB) 的研究报告的副本
- 股市：红海中的三个力量之岛
- 第四季度值得考虑的3家银行
- MarketBeat：本周回顾 9/12 — 9/16
- 没有人告诉这三只股票这是下跌的一周
- 有办法治愈Teladoc Stock的病吗？
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Genmab A/S Daily 的新闻和评级 -在下面输入您的电子邮件地址，通过Marketbeat.com的免费每日电子邮件时事通讯接收Genmab A/S及相关公司的最新新闻和分析师评级的简明每日摘要。